The aggressive characteristics of MCL and CLL, which can evolve into a more severe form, frequently necessitate intensive treatment protocols, including high-dose chemotherapy and targeted therapies such as BTK inhibitors (e.g., ibrutinib). Here, BTK is linked to B-cell chronic lymphocytic leukemia.